GHK-Cu 100mg + KPV 10mg Research Bundle
USA Made, ≥99% Purity Per Compound
4.9 177 verified reviews- Separate retail vials: GHK-Cu 100mg; KPV 10mg
- USA manufactured in a Certified GMP California and Arizona laboratory.
- ≥99% purity target per compound with third-party HPLC, mass spectrometry, and batch-specific COAs
For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.
Per-compound specifications
2 vialsNothing in this bundle is co-formulated. Each vial keeps its own identity, purity target, and certificate, and is specified separately below.
- CAS
- 89030-95-5
- Molecular mass
- 402.92 g/mol
- Purity target
- ≥99%
- Form
- Lyophilized Powder
- CAS
- 67727-97-3
- Molecular mass
- 342.43 g/mol
- Purity target
- ≥99%
- Form
- Lyophilized Powder
- Form
- 2 Separate Lyophilized Powders
- Purity target
- ≥99% per compound (3rd-Party HPLC Tested)
- Origin
- All Included Products: Synthesized, Formulated & Packaged in CA/AZ, USA
- Storage
- Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light
What is the GHK-Cu and KPV Research Bundle?
This two-vial bundle pairs GHK-Cu 100mg with KPV 10mg. GHK-Cu is a copper complex formed by the Gly-His-Lys tripeptide and a copper ion, while KPV is the compact Lys-Pro-Val C-terminal sequence of alpha-MSH.
The separate products support controlled research across copper coordination, extracellular-matrix signaling, peptide transport, and inflammatory-response pathways. The bundle is not a finished cosmetic, drug product, or combined formulation.
How It Works
GHK-Cu binds and carries copper: Researchers study copper coordination, fibroblast activity, gene expression, and extracellular-matrix remodeling.
KPV isolates a three-residue signal: Cell models examine PepT1 transport and changes in NF-κB, MAPK, and downstream cytokine responses.
Separate vials preserve experimental control: Each compound can be evaluated independently or compared without assuming a combined effect.
One certificate per vial
Independent third-party HPLC assesses each compound against its ≥99% purity target, while mass spectrometry confirms identity. For each vial, the results are documented in one combined, batch-specific COA report.
- Lot
- KP-47494
- Reported
- 2026-05-12
- Identity (LC-MS)
- Confirmed
- Purity (HPLC-UV)
- 99.49%
- Net content
- 10.04 mg
- Appearance
- White lyophilized powder
Why Source from 321 Peptides?
Lot history 7 released lots
Every batch released under each vial in this bundle, with the figure reported for each. Vials are shipped from current stock.
| Compound | Lot | Reported | Purity | Net content | COA |
|---|---|---|---|---|---|
| GHK-Cu 100mg | GH-50595 | 2026-04-30 | 99.58% | 100.00 mg | Pending |
| GH-51749 | 2026-04-23 | 99.49% | 100.20 mg | Pending | |
| GH-51172 | 2026-02-25 | 99.83% | 100.10 mg | Pending | |
| KPV 10mg | KP433 | 2026-06-01 | 99.30% | 10.48 mg | |
| KP-47494 | 2026-05-12 | 99.49% | 10.04 mg | Pending | |
| KP-46917 | 2026-05-02 | 99.83% | 10.03 mg | Pending | |
| KP-48071 | 2026-04-30 | 99.46% | 10.05 mg | Pending |
